Overview
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2029-06-01
2029-06-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Curium US LLCTreatments:
Prednisone
Criteria
Inclusion Criteria:1. Male 18 years or older able to understand and provide signed written informed consent.
2. Histologically or pathologically confirmed prostate adenocarcinoma without predominant
small cell component.
3. Progressive disease by one or more of the following criteria:
1. Serum/plasma PSA progression defined as 2 consecutive increases in PSA over a
previous reference value measured at least 1 week apart with a minimum start
value of >2 ng/mL.
2. Progression of measurable disease (RECIST 1.1) or presence of at least two new
bone lesions (PCWG3 criteria).
4. Previous treatment with next-generation androgen receptor (AR)-directed therapy (e.g.
abiraterone, enzalutamide, apalutamide, darolutamide).
1. Must have received no more than one previous AR-directed therapy.
2. Must have been administered ARAT (abiraterone, enzalutamide, darolutamide, or
apalutamide) in the castration-sensitive or castration-resistant setting.
3. Must have progressed while on ARAT.
5. PSMA-PET scan (e.g., 68Ga-PSMA-11 or 18F-DCFPyL) positive as determined by central
reader.
6. Effective castration with serum testosterone level of <50 ng/dL and plan to continue
with chronic medical or surgical castration.
7. Ability to attend required study visits and return for adequate follow-up, as required
by this protocol.
8. Patients with HIV that are healthy and with a low risk of acquired immune deficiency
syndrome related outcomes may participate in the trial at the investigators'
discretion.
9. Patients with HBV and HCV may also participate if symptoms are sufficiently managed.
10. Life expectancy of at least 6 months as assessed by investigator.
11. Willing to initiate ARAT therapy determined by investigator.
12. For patients who have partners of childbearing potential: The patient and/or partner
must use a method of birth control with adequate barrier protection, deemed acceptable
by the principal investigator during the study and for 6 months after the last study
drug administration.
Exclusion Criteria:
1. Prior treatment with radioligand therapy including other lutetium-labeled compounds.
2. Prior treatment with radium-223 (Xofigo) within the past 12 weeks.
3. Prior chemotherapy treatment for castration-sensitive or castration-resistant prostate
cancer (docetaxel or cabazitaxel).
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2
5. Patients with known HRR gene-mutation who have not been previously treated with
olaparib or rucaparib.
6. Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or
investigational therapy.
7. Inadequate organ and bone marrow function as evidenced by:
1. Hemoglobin < 8 g/dL.
2. Absolute neutrophil count < 1.5 x 109/L.
3. Platelet count < 100 x 109/L.
4. AST/SGOT and/or ALT/SGPT > 3.0 x ULN.
5. Total bilirubin > 2 x ULN unless patient has known Gilbert's syndrome and then
may be 3 x ULN.
6. Creatinine clearance (CrCl) < 50 mL/min based on the Cockcroft-Gault equation.
7. Albumin ≥ 2.75 g/dL
8. Patients who undergo a transfusion for the sole purpose of meeting eligibility for
this trial will be excluded.
9. Assessment by the Investigator as unable or unwilling to comply with the requirements
of the protocol.
10. Use of an investigational therapeutic drug within the last 4 weeks prior to start of
study treatment or scheduled to receive one during the study period.
11. Known CNS metastasis unless received therapy, asymptomatic and neurologically stable.
12. Patients receiving zoledronic acid for bone-targeted therapy must be on stable dose
for 4 weeks prior to randomization.
13. Major surgery within 30 days of randomization as determined by the Investigator.
14. Patients with active significant cardiac disease defined by any of the following:
1. New York Heart Association class 3 or 4 congestive heart failure within 6 months
of signing the ICF unless treated with improvement.
2. Current diagnosis of electrocardiogram abnormalities with significant cardiac
arrhythmias
3. History of long QT syndrome or know history of Torsades de Pointe
4. History of myocardial infarction, angina pectoris, or coronary artery bypass
graft within 6 months of ICF signature
15. Participants with symptomatic cord compression or clinical/radiological findings
indicating impending spinal cord compression
16. Patients with a superscan seen on baseline bone scan as determined by investigator.
17. Active malignancy other than low-grade non-muscle-invasive bladder cancer and
non-melanoma skin cancer
18. Previous use of G-CSF for persistent neutropenia after standard of care treatment.
19. Participants who have a pregnant partner or are capable of fathering a child and who
are unwilling to take precautions to prevent potential harm to the fetus or prevent
pregnancy.
20. Participants with active Covid19. Recovered patients may be included when completely
recovered (no symptoms at least 28 days before study medication and a negative Covid
test within 72 hours).